Arms 1 vs. 2:Median duration of response: 17.0 vs. 0 weeksPFS in wild-type KRAS mCRC: HR = 0.454 (95% CI, 0.44-0.66) favoring panitumumab armObjective response rates also favored panitumumab (10% vs. 0%), P < .0001No differences in OSDermatologic toxicities: 90%Ocular toxicities: 15%Incidence of paronychia was 25% with 2% of severe casesArm 1 vs. 2: Gr ≥3Acneiform dermatitis: 7% vs. 0%Dyspnea: 5 vs. 3%One patient experienced Gr 3 event of mucosal inflammation11% of patients treated with panitumumab reported severe toxicity leading to dose interruption. Here, KRAS is linked to skin disorder.